NCT07101536View on ClinicalTrials.gov

The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
EBV-associated Tumors
Interventions
BIOLOGICAL

EBV mRNA vaccine

EBV mRNA vaccine

BIOLOGICAL

Immune Checkpoint Inhibitors, ICIs

Immune Checkpoint Inhibitors, ICIs

All Listed Sponsors
lead

West China Hospital

OTHER

NCT07101536 - The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV) | Biotech Hunter | Biotech Hunter